课题基金 / 基金详情

XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGY

XOLAIR IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH FOOD ALLERGY
XOLAIR 用于患有食物过敏的中度至重度特应性皮炎的受试者
批准号:
7375254
负责人:
RICHARD Barry MOSS
金额:
$1.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-12-01 至 2006-11-30

项目摘要

项目成果

RICHARD Barry MOSS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study to determine the safety of an anti-IgE momoclonal antibody (Omalizumab, also called Xolair) in treating children with moderate to severe atopic dermatitis and food allergies. The dosing phase will last three to six months, and follow up will continue for two years to determine if Xolair has any effect in reducing the development of hay fever and asthma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A PHASE I/II, SINGLE-CENTER, BLINDED, RANDOMIZED, CONTROLLED STUDY OF XOLAIR
  • 批准号:
    7605198
  • 项目类别:
  • 资助金额:
    $0.82万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
CLINICAL TRIAL: VX-770 CFTR ACTIVITY IN CYSTIC FIBROSIS (CF) SUBJECTS WITH GENOT
  • 批准号:
    7717937
  • 项目类别:
  • 资助金额:
    $0.1万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
PTC124 AS AN ORAL TREATMENT FOR NONSENSE-MUTATION-MEDIATED CYSTIC FIBROSIS
  • 批准号:
    7605255
  • 项目类别:
  • 资助金额:
    $1.4万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
DIABETES THERAPY IN CF PATIENTS WITH ABNORMAL GLUCOSE TOLERANCE
  • 批准号:
    7605163
  • 项目类别:
  • 资助金额:
    $0.12万
  • 财政年份:
    2007
  • 负责人:
    RICHARD Barry MOSS
  • 依托单位:
海外基金